[DRRX] DURECT Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 195.05 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.28 Change: 0.04 (3.23%)
Ext. hours: Change: 0 (0%)

chart DRRX

Refresh chart

Strongest Trends Summary For DRRX

DRRX is in the long-term down -64% below S&P in 1 year and down -77% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company?s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase

Fundamental Ratios
Shares Outstanding137.36 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 4.19% Sales Growth - Q/Q11.81% P/E
P/E To EPS Growth P/S10.91 P/BV12.6 Price/Cash Per Share6.72
Price/Free Cash Flow-13.53 ROA-51.33% ROE-150.97% ROI-65.53%
Current Ratio5.02 Quick Ratio4.5 Long Term Debt/Equity0.62 Debt Ratio0.47
Gross Margin68.52% Operating Margin-122.01% Net Profit Margin-130.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities240 K Cash From Investing Activities4.42 M Cash From Operating Activities-5.35 M Gross Profit3.77 M
Net Profit-4.85 M Operating Profit-4.42 M Total Assets45.52 M Total Current Assets36.47 M
Total Current Liabilities7.26 M Total Debt19.84 M Total Liabilities30.04 M Total Revenue4.77 M
Technical Data
High 52 week2.2 Low 52 week0.48 Last close0.75 Last change0.36%
RSI64.48 Average true range0.1 Beta1.39 Volume369.5 K
Simple moving average 20 days12.37% Simple moving average 50 days10.63% Simple moving average 200 days-12.95%
Performance Data
Performance Week3.06% Performance Month28.47% Performance Quart0.74% Performance Half-13.29%
Performance Year-61.77% Performance Year-to-date54.32% Volatility daily9.52% Volatility weekly21.29%
Volatility monthly43.62% Volatility yearly151.12% Relative Volume282.28% Average Volume515.19 K
New High New Low

News

2019-06-20 08:00:00 | DURECT Announces $15 Million Registered Direct Offering

2019-06-18 08:00:00 | DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis AH in its Ongoing DUR-928 Phase 2a AH Trial

2019-06-11 10:45:16 | Some DURECT NASDAQ:DRRX Shareholders Have Taken A Painful 75% Share Price Drop

2019-05-17 10:50:00 | DRRX: Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event

2019-05-16 16:15:00 | DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

2019-05-09 12:04:21 | Edited Transcript of DRRX earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-08 11:40:00 | DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

2019-05-08 07:53:50 | The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

2019-05-08 06:30:00 | DURECT Corp. to Host Earnings Call

2019-05-08 05:04:23 | Durect: 1Q Earnings Snapshot

2019-05-07 21:03:00 | DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

2019-05-07 17:42:00 | DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs

2019-05-07 08:20:52 | The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

2019-05-03 13:26:00 | DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results

2019-04-25 08:00:00 | DURECT Appoints Two New Board Members

2019-04-22 15:24:24 | DURECT Corporation NASDAQ:DRRX: What's The Analyst Consensus Outlook?

2019-04-01 08:00:00 | DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH

2019-03-27 08:00:00 | DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis NASH

2019-03-21 08:00:00 | DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis

2019-03-13 16:00:00 | DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year

2019-03-08 22:43:02 | Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-08 21:48:14 | Durect Corp DRRX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-07 16:05:00 | DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs

2019-03-04 08:00:00 | DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call

2019-02-27 07:00:00 | DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter

2019-02-26 12:00:12 | DURECT Corporation NASDAQ:DRRX: Time For A Financial Health Check

2019-02-22 07:20:00 | Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth

2019-02-21 08:00:00 | DURECT Corporation to Participate in the Berenberg NASH Day

2019-01-24 07:00:00 | Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug

2019-01-11 11:45:00 | DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications

2019-01-07 07:30:00 | DURECT Corporation Provides Corporate Update

2019-01-04 06:59:02 | Here’s What We Think About DURECT Corporation’s NASDAQ:DRRX CEO Pay

2019-01-03 16:30:00 | DURECT Corporation Announces Investor Call to Provide Corporate Update

2018-12-19 08:00:00 | Commercial Launch Plans Announced for PERSERIS™ risperidone Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

2018-12-17 08:00:00 | DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist

2018-11-30 07:55:00 | Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-19 08:00:00 | DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis AH by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients

2018-11-16 14:30:00 | DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream

2018-11-13 13:44:00 | Could DURECT Corporation’s NASDAQ:DRRX Investor Composition Influence The Stock Price?

2018-11-09 03:17:05 | Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 17:13:14 | Durect: 3Q Earnings Snapshot

2018-11-07 16:01:00 | DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-01 16:15:00 | DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call

2018-10-25 08:00:00 | DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings

2018-10-23 08:20:00 | Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-01 08:00:00 | DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer

2018-09-25 08:00:00 | DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-19 12:50:42 | Is DURECT Corporation’s NASDAQ:DRRX Balance Sheet Strong Enough To Weather A Storm?

2018-09-18 08:00:00 | DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan

2018-08-30 08:00:00 | DURECT Announces Receipt of $5 Million Milestone Payment from Indivior